Immatics N.V.
For the period ended Oct 24, 2026. Filed Oct 26, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Oct 24, 2026 · Filed Oct 26, 2026
Use the contents to explore the available documents and sections.
Contents
Next Development Steps
The promising clinical profile of IMA402 supports a development path across various solid tumors in earlier and later treatment lines. These include combination approaches with ICIs in melanoma and in gynecologic cancers as well as IMA402 in combination with the Company’s MAGEA4/8-directed bispecific, IMA401, in lung cancer with first data expected in 2027. Furthermore, the use of Immatics’ proprietary rapid, sensitive and reliable liquid biopsy-based PRAME testing enables precise patient selection and could support potential fast-to-market strategies, subject to regulatory approval, in PRAME-high melanoma and beyond.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.